The influence of the ratio of liver cells and bone marrow in the implantable cell-engineering structures of the liver on the recovery efficiency of functional and morphological parameters in chronic liver failure

Aim: to determinate the most effective liver cells and multipotent mesenchymal stromal cells of bone marrow (MMSC BM) ratio into implantable cell engineering constructions (CECs) used for chronic liver failure (CLF) correcting.

Materials and methods. For creating liver CECs it was used a biopolymer implant – a composition of a heterogeneous collagen-containing gel (BMCG) (Sphero®GEL trademark) containing viable liver cells and MMSC BM in the following ratios – 1 : 1; 5 : 1 and 10 : 1 respectively. CECs with different ratios of liver cells and MMSC BM were implanted into liver of rats in which chronic liver failure (CLF), was modeled by using CCl4. The effectiveness of the regulatory effects of CECs (with different cell ratios) on regenerative processes in livers were assessed by using biochemical, morphological and morphometric methods at different periods after their implantation.

Results. Corrective effect of CECs with different cell composition on biochemical and morphological parameters of livers at chronic liver failure was established. During studying the liver CECs with various cell ratios of liver cells and MMSC BM (1 : 1; 5 : 1 and 10 : 1 respectively), it was found that the most optimal ratio of cells into the CECs is 5 : 1, because at this ratio of cells, there were a more distinct normalization of the morphological and functional liver parameters within 365 days after modeling CLF and maintenance of the structural homeostasis into the CECs. Themselves, which allows predicting their long-term regulatory effect on the liver tissue in CLF and maintaining its normal structural and functional state.

Conclusion. The effective correction of chronic liver failure can be carried out by using the implanted liver CECs, in which donor liver cells and MMSC BM where presented in ratios – 1 : 1; 5 : 1 and 10 : 1. But analysis of prolonged correction of liver morphological and functional parameters at CECs using it was allow to recommend the preferences using of CECs with ratio 5 : 1, because prolonged preservation of structural homeostasis into these CECs makes possible to prognosticate their prolonged regulatory action on the liver tissue at CLF, especially for recipients on a waiting list for liver transplantation.

1. WHO. World health statistics 2016: monitoring health for the SDGs, sustainable development goals. World Health Organization, Geneva; 2016.

2. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015; 385: 117–171.

3. Forbes S, Strom S. Stem Cells and Hepatocyte Transplantation. A Textbook of Liver Disease. 2018: 84–97.e3. https://doi.org/10.1016/B978-0-323-37591-7.00006-9.

4. Forbes SJ, Gupta S, Dhawan A. Cell therapy for liver disease: From liver transplantation to cell factory. J Hepatol. 2015; 62 (1 Suppl): 157–169. doi: 10.1016/j.jhep.2015.02.040.

5. Gautier SV, Konstantinov BA, Tsirul’nikova OM. Transplantatsiya pecheni. M.: MIA, 2008: 246.

6. United Network for Organ Sharing. [Электронный ресурс] – Режим доступа: http://www. unos.org.

7. Eurotransplant international foundation. Annual Report [Электронный ресурс] – Режим доступа: www.eurotransplant.nl/files/statistics.

8. Hughes RD, Mitry RR, Dhawan A. Current status of hepatocyte transplantation. Transplantation. 2012; 93: 342–347. doi: 10.1097/TP.0b013e31823b72d6.

9. Burkhardt B, Martinez-Sanchez JJ, Bachmann A, Ladurner R, Nüssler AK. Long-term culture of primary hepatocytes: new matrices and microfluidic devices. Hepatology International. 2014; 8: 14–22. doi: 10.1007/s12072-013-9487-3/.

10. Gupta S .Cell therapy to remove excess copper in Wilson’s disease. Annals of the New York Academy of Sciences. 2014; 1315, Issue 1: 70–80. doi: 10.1111/nyas.12450/.

11. Tanimizu N, Ichinohe N, Ishii M, Kino J, Mizuguchi T, Hirata K, Mitaka T. Liver Progenitors Isolated from Adult Healthy Mouse Liver Efficiently Differentiate to Functional Hepatocytes In Vitro and Repopulate Liver Tissue. Stem Cells. 2016; 34, Issue 12: 2889–2901. doi: 10.1002/stem.2457/.

12. Yovchev MI, Xue Y, Shafritz DA, Locker J, Oertel M. Repopulation of the fibrotic/cirrhotic rat liver by transplanted hepatic stem/progenitor cells and mature hepatocytes. Hepatology. 2014; 59: 284–295. doi: 10.1002/hep.26615/.

13. Grompe M. Liver stem cells, where art thou? Cell Stem Cell. 2014; 15: 257–258. doi: 10.1016/j.stem.2014.08.004.

14. Ichinohe N, Tanimizu N, Ooe H et al. Differentiation capacity of hepatic stem/pro-genitor cells isolated from Dgalactosamine-treated rat livers. Hepatology. 2013; 57: 1192–1202.

15. Mallanna SK, Duncan SA. Differentiationof hepatocytes from pluripotent stem cells. Curr Protoc Stem Cell Biol. 2013; 26: Unit1G 4.

16. Irudayaswamy A, Muthiah M, Zhou L et al. Long-term fate of human fetal liver progenitor cells transplanted in injured mouse livers. Stem Cells. 2018; 36: 103–113.

17. Soeder Y, Loss M, Johnson CL, Hutchinson JA, Haarer J, Ahrens N et al. First-in-Human Case Study: Multipotent Adult Progenitor Cells for Immunomodulation After Liver Transplantation. Stem Cells Transl Med. 2015; 4 (8): 899–904. doi: 10.5966/sctm.2015-0002.

18. Dillmann J, Popp FC, Fillenberg B, Zeman F, Eggenhofer E, Farkas S et al. Treatment-emergent adverse events after infusion of adherent stem cells: the MiSOT-I score for solid organ transplantation. Trials. 2012; 15 (13): 211–221. doi: 10.1186/1745-6215-13-211.

19. Popp FC, Fillenberg B, Eggenhofer E, Renner P, Dillmann J, Benseler V et al. Safety and feasibility of thirdparty multipotent adult progenitor cells for immunomodulation therapy after liver transplantation – a phase I study (MISOT-I). J Transl Med. 2011; 28 (9): 124. doi: 10.1186/1479-5876-9-124.

20. Chistiakov DA. Liver regenerative medicine: advances and challenges. Cells Tissues Organs. 2012; 4 (196): 291–312.

21. Lee SY, Kim HJ, Choi D. Cell Sources, Liver Support Systems and Liver Tissue Engineering: Alternatives to Liver Transplantation. International Journal of Stem Cells. 2015; 8 (1): 36–47. doi: 10.15283/ijsc.2015.8.1.36.

22. Matsuzawa A, Matsusaki M, Akashi M. Construction of three-dimensional liver tissue models by cell accumulation technique and maintaining their metabolic functions for long-term culture without medium change. J Biomed Mater Res A. 2015 Apr; 103 (4): 1554–1564. doi: 10.1002/jbm.a.35292. Epub 2014 Aug 12.

23. Sakai Y, Yamanouchi K, Ohashi K. Vascularized subcutaneous human liver tissue from engineered hepatocyte/ fibroblast sheets in mice. Biomaterials. 2015; 65: 66–75. doi: 10.1016/j.biomaterials.2015.06.046.

24. Fujii M, Yamanouchi K, Sakai Y, Baimakhanov Z, Yamaguchi I, Soyama A et al. In vivoconstruction of liver tissue by implantation of ahepatic non-parenchymal/ adipose-derived stem cellsheet. J Tissue Eng Regen Med. 2017; 21. doi: 10.1002/term.2424.

25. Shu Q Liu. Bioregenerative Engineering: Principles and Applications. Wiley-interscience A. John Willey & Sons, inc., Hoboken, New Jersey Publication. 2007. 1053 p.

26. Zhang J, Zhao X, Liang L, Wang S. A decade of progress in liver regenerative medicine Review article. Biomaterials. 2018; 157: 161–176. doi: 10.1016/j.biomaterials.2017.11.027.

27. Sasaki K, Akagi T, Asaoka T, Eguchi H, Akashi M. Construction of three-dimensional vascularized functional human liver tissue using a layer-by-layer cell coating technique. Biomaterials. 2017; 133: 263–274.

28. Nicolas C, Hickey R, Chen H, Mao S, Higuita M, Wang Y, Nyberg S. Liver Regenerative Medicine: From Hepatocyte Transplantation to Bioartificial Livers and Bioengineered Grafts. Stem Cells. 2017; 35 (1): 42–50.

29. Ishak K et al. Gistologicheskaya otsenka stadii i stepeni khronicheskogo gepatita. Klinicheskaya gepatologiya. 2010; 2: 8–11.

30. Avtandilov GG. Meditsinskaya morfometriya: rukovodstvo. M.: Meditsina, 1990. 384.